Literature DB >> 629859

Growth characteristics of human colorectal tumours during serial passage in immune-deprived mice.

J A Houghton, D M Taylor.   

Abstract

The growth characteristics of 6 human colorectal tumours have been examined during serial passage in both male and female immune-deprived mice. Exponential growth is a characteristic feature, especially on very early passages. Growth rates in 5 out of the 6 tumour lines increase during the first few transplant generations. This is accompanied by a shorter exponential growth phase and an increased slope of the growth curves. Lag phases and growth rates for individual tumours are variable within a passage. Growth rates for tumours maintained within the same host are similar, and are at least partially influenced by the host. In one tumour line examined in detail, the increased growth rate is attributable to a decreased cell-loss factor, and the difference in growth rate between human colorectal tumours and their corresponding xenografts may therefore largely be due to a difference in the contribution of this factor.

Entities:  

Mesh:

Year:  1978        PMID: 629859      PMCID: PMC2009585          DOI: 10.1038/bjc.1978.29

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  THE RATES AND PATTERNS OF GROWTH OF 375 TUMORS OF THE LARGE INTESTINE AND RECTUM OBSERVED SERIALLY BY DOUBLE CONTRAST ENEMA STUDY (MALMOE TECHNIQUE).

Authors:  S WELIN; J YOUKER; J S SPRATT
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1963-10

2.  CELL PROLIFERATION KINETICS IN THE GASTROINTESTINAL TRACT OF MAN. I. CELL RENEWAL IN COLON AND RECTUM.

Authors:  M Lipkin; B Bell; P Sherlock
Journal:  J Clin Invest       Date:  1963-06       Impact factor: 14.808

3.  Analysis of the cell kinetics of human solid tumors.

Authors:  J J Terz; H P Curutchet; W Lawrence
Journal:  Cancer       Date:  1971-11       Impact factor: 6.860

4.  Growth kinetics of human large bowel cancer growing in immune-deprived mice and some chemotherapeutic observations.

Authors:  L F Lamerton; G G Steel
Journal:  Cancer       Date:  1975-12       Impact factor: 6.860

5.  The therapeutic response of three human tumor lines maintained in immune-suppressed mice.

Authors:  L Kopper; G G Steel
Journal:  Cancer Res       Date:  1975-10       Impact factor: 12.701

6.  Effects of cytotoxic agents on TdR incorporation and growth delay in human colonic tumour xenografts.

Authors:  P J Houghton; J A Houghton; D M Taylor
Journal:  Br J Cancer       Date:  1977-08       Impact factor: 7.640

7.  The growth kinetics of xenografts of human colorectal tumours in immune deprived mice.

Authors:  R G Pickard; L M Cobb; G G Steel
Journal:  Br J Cancer       Date:  1975-01       Impact factor: 7.640

Review 8.  The growth rate of human tumours.

Authors:  G G Steel; L F Lamerton
Journal:  Br J Cancer       Date:  1966-03       Impact factor: 7.640

9.  A method of comparing differences in tumour growth rates applied to a study of the increasing growth capacity of mouse carcinomata.

Authors:  J A Rees; M Westwood
Journal:  Br J Cancer       Date:  1974-02       Impact factor: 7.640

10.  Maintenance of biological and biochemical characteristics of human colorectal tumours during serial passage in immune-deprived mice.

Authors:  J A Houghton; D M Taylor
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

View more
  27 in total

1.  Mutants of human colon adenocarcinoma, selected for thymidylate synthase deficiency.

Authors:  P J Houghton; G S Germain; B J Hazelton; J W Pennington; J A Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

Review 2.  Human tumor xenografts as model for drug testing.

Authors:  J Mattern; M Bak; E W Hahn; M Volm
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

3.  Monitoring the development of xenograft triple-negative breast cancer models using diffusion-weighted magnetic resonance imaging.

Authors:  Renu M Stephen; Mark D Pagel; Kathy Brown; Amanda F Baker; Emmanuelle J Meuillet; Robert J Gillies
Journal:  Exp Biol Med (Maywood)       Date:  2012-11

Review 4.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

5.  Correlative effect between in vivo hollow fiber assay and xenografts assay in drug screening.

Authors:  Keyong Ho Lee; Ki Hyeong Rhee
Journal:  Cancer Res Treat       Date:  2005-06-30       Impact factor: 4.679

Review 6.  Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy.

Authors:  P J Houghton; J A Houghton; B J Hazelton; S Radparvar
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

7.  Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma.

Authors:  D N Shapiro; B G Jones; L H Shapiro; P Dias; P J Houghton
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

8.  The potential of the nude mouse xenograft model for the study of head and neck cancer.

Authors:  B J Braakhuis; G Sneeuwloper; G B Snow
Journal:  Arch Otorhinolaryngol       Date:  1984

9.  Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts.

Authors:  J A Houghton; L G Williams; S K Loftin; P J Cheshire; C L Morton; P J Houghton; A Dayan; J Jolivet
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.

Authors:  P J Houghton; P J Cheshire; L Myers; C F Stewart; T W Synold; J A Houghton
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.